<DOC>
	<DOC>NCT00686504</DOC>
	<brief_summary>The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace [11C]AZ12713580 from mGluR5 binding-sites in the Central Nervous System</brief_summary>
	<brief_title>Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066</brief_title>
	<detailed_description />
	<criteria>Provision of informed consent BMI (Body Mass Index) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg Normal MRI (Magnetic Resonance Imaging) scan at visit 2 History of previous or ongoing psychiatric disease or condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders History of psychotic disorder among first degree relatives (parents, siblings) History of use of antipsychotic, antidepressant or anxiolytic (anxiety treatment) drugs, prescribed or nonprescribed use. History of antidepressants or anxiolytics for nonpsychiatric conditions such as pain or postoperative insomnia is allowed</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Pain</keyword>
	<keyword>PET</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Analgesia</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>mGlu5 receptor</keyword>
	<keyword>Dose finding</keyword>
	<keyword>Analgesia/Pain</keyword>
</DOC>